Healthcare Boston, MA 310 employees
Rare Disease Specialty Pharma Platform
Specialty pharmaceutical company with 3 FDA-approved products and a robust clinical pipeline
About This Business
Meridian Specialty Pharma develops and commercializes specialty pharmaceutical products focused on rare neurological and autoimmune conditions. The company has three FDA-approved products generating $89M in net revenue with growing market share in each indication. A pipeline of two Phase II candidates and one Phase III candidate provides significant upside optionality beyond the base business.
Key Highlights
3 FDA-approved products generating $89M in net revenue with 20%+ EBITDA margins
Phase III candidate in rare epilepsy expected to file NDA in Q3 2027
Specialty sales force of 65 reps covering 92% of target prescribers
Patent protection on lead product through 2034 with additional method-of-use patents pending
Established relationships with specialty pharmacy networks covering 85% of covered lives
Financial Overview
Reason for Selling
VC and crossover investors are seeking liquidity after a 6-year hold. Management team is committed to staying through a transition to the right acquirer.
Documents Available in Data Room
Financial Statements
Tax Returns
Legal Documents
Operational Documents
Marketing Materials
Estimated Value
$111.3M – $137.9M
Asking Price
$124.6M
Company name and seller contact revealed after purchase. One-time fee.